Tributary Capital Management LLC Raises Stock Holdings in Enovis Co. (NYSE:ENOV)

Tributary Capital Management LLC grew its stake in shares of Enovis Co. (NYSE:ENOV - Free Report) by 33.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 566,089 shares of the company's stock after purchasing an additional 143,258 shares during the period. Enovis makes up 1.9% of Tributary Capital Management LLC's investment portfolio, making the stock its 15th biggest holding. Tributary Capital Management LLC owned about 1.01% of Enovis worth $24,840,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in ENOV. River Road Asset Management LLC bought a new position in shares of Enovis in the third quarter valued at $51,341,000. Royce & Associates LP increased its holdings in Enovis by 16.8% during the 3rd quarter. Royce & Associates LP now owns 2,403,685 shares of the company's stock worth $103,479,000 after purchasing an additional 346,317 shares in the last quarter. Diamond Hill Capital Management Inc. raised its stake in shares of Enovis by 7.8% in the third quarter. Diamond Hill Capital Management Inc. now owns 3,004,694 shares of the company's stock worth $129,352,000 after purchasing an additional 218,660 shares during the last quarter. Artemis Investment Management LLP boosted its position in shares of Enovis by 35.4% during the fourth quarter. Artemis Investment Management LLP now owns 665,868 shares of the company's stock valued at $29,218,000 after buying an additional 174,116 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Enovis by 9.5% during the third quarter. Geode Capital Management LLC now owns 921,437 shares of the company's stock valued at $39,678,000 after buying an additional 80,165 shares during the last quarter. Institutional investors own 98.45% of the company's stock.

Analyst Ratings Changes

Several research firms have recently issued reports on ENOV. Needham & Company LLC reiterated a "buy" rating and issued a $65.00 target price on shares of Enovis in a research note on Thursday, November 7th. JMP Securities assumed coverage on shares of Enovis in a research report on Thursday, October 3rd. They issued an "outperform" rating and a $62.00 price objective for the company. Finally, Evercore ISI dropped their target price on shares of Enovis from $62.00 to $58.00 and set an "outperform" rating on the stock in a research report on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, Enovis has a consensus rating of "Moderate Buy" and a consensus target price of $65.86.

Enovis Stock Performance

ENOV traded up $0.51 during midday trading on Friday, reaching $47.78. The company had a trading volume of 744,387 shares, compared to its average volume of 1,123,152. Enovis Co. has a 12-month low of $38.27 and a 12-month high of $65.03. The business has a 50-day moving average price of $45.93 and a two-hundred day moving average price of $44.46. The stock has a market cap of $2.67 billion, a PE ratio of -21.82 and a beta of 1.94. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27.

Enovis (NYSE:ENOV - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.73 EPS for the quarter, topping analysts' consensus estimates of $0.62 by $0.11. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The company had revenue of $505.22 million for the quarter, compared to analysts' expectations of $504.44 million. During the same quarter in the previous year, the firm posted $0.56 EPS. Enovis's revenue was up 21.0% on a year-over-year basis. On average, sell-side analysts expect that Enovis Co. will post 2.79 earnings per share for the current fiscal year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.